Biotest AG (HAM:BIO) Stock Based Compensation: €0.0 Mil (TTM As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:BIO Biotest AG HAM:BIO
56 GF Score
Price €40.00
View Full Analysis

What is Biotest AG Stock Based Compensation?

Biotest AG HAM:BIO +2.04% 56 Stock Based Compensation is €0.0 Mil as of Mar. 2025. GuruFocus rates HAM:BIO with a GF Score™ of 56/100.

Biotest AG's Stock Based Compensation for the three months ended in Mar. 2025 was €0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Biotest AG Stock Based Compensation Related Terms

Biotest AG Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Biotest AG's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest AG Stock Based Compensation Chart

Biotest AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biotest AG Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:BIO
56GF Score
Biotest AG HAM:BIO
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biotest AG Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

What does a Stock Based Compensation of €0.0 Mil mean?
Biotest AG (HAM:BIO) has a Stock Based Compensation of €0.0 Mil as of Mar. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Biotest AG and its competitors.
Is Biotest AG's Stock Based Compensation too high?
Biotest AG's current Stock Based Compensation is €0.0 Mil. Overall, Biotest AG has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Biotest AG's Stock Based Compensation compare to VRTX and REGN?
Biotest AG's Stock Based Compensation of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Biotest AG and its competitors. Biotest AG's current Stock Based Compensation is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest AG stock overvalued right now?
Biotest AG (HAM:BIO) has a current Stock Based Compensation of €0.0 Mil. The current Stock Based Compensation is €0.0 Mil. Biotest AG's overall GF Score™ is 56/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Biotest AG (HAM:BIO), the current Stock Based Compensation is €0.0 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest AG Business Description

Address Landsteinerstrasse 5, PO Box 10 20 40, Dreieich, DEU, 63303
Biotest AG is a supplier of biological medicines. The company produces its products from human blood plasma or manufactured by using biotechnology methods. It is engaged in the area of hematology, clinical immunology, and intensive care medicine. The company covers preclinical and clinical development of the preparations, plasma collection, production, as well as marketing and sales.
56GF Score

Get the complete analysis for HAM:BIO

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.00
Price